Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells

(2009) C. P. Miller et al.   BLOOD

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

(2009) G. Bianchi et al.   BLOOD

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis

(2009) Susan Fotheringham et al.   CANCER CELL

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

(2009) A. Badros et al.   CLINICAL CANCER RESEARCH

Expression Levels of Histone Deacetylases Determine the Cell Fate of Hematopoietic Progenitors

(2009) Taeko Wada et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells

(2009) T Rückrich et al.   LEUKEMIA

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

(2009) Teresa A. Soucy et al.   NATURE

Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25

(2008) J. Chen et al.   BLOOD

Bortezomib in the front-line treatment of multiple myeloma

(2008) Paul G Richardson et al.   Expert Review of Anticancer Therapy

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

(2008) Xiang-Jiao Yang et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

(2008) K Hatano et al.   ONCOGENE